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Review Article
Leptin and Its Emerging Role in Children and Adolescents
Iosif Kelesidis and Christos S. Mantzoros
Division of Endocrinology, Diabetes, & Metabolism, Department of Medicine, Beth Israel Deaconess Medical
Center, Harvard Medical School, Boston, Massachusetts, 02215, USA
Abstract.  Leptin is an adipocyte-secreted hormone which plays a key role in energy homeostasis.
Recent “proof of concept” studies involving leptin administration to humans support its critical role in
regulating energy homeostasis, neuroendocrine and immune function as well as insulin resistance in
states of energy/ caloric deprivation.  Moreover, interventional studies in leptin deficient children and
observational studies in normal girls and boys support a role for leptin as a permissive factor for the
initiation of puberty in children.  The potential clinical usefulness of leptin in several disease states in
children and adolescents, including hypothalamic amenorrhea, eating disorders and syndromes of
insulin resistance is still under investigation.
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Introduction
Leptin is a 16 Kd adipocyte-secreted protein.
Although originally discovered as an obesity
associated hormone (1), subsequent clinical trials
revealed that obesity is a leptin resistant state
(2).  The increasing prevalence of obesity in
children and adolescents, (currently 15% in the
USA) (3) underlies the importance of leptin
research in elucidating the pathophysiology of
obesity in children.  Since the role of leptin might
be more important in energy-deficient states,
however, leptin’s role has also been studied in
disease states such as exercise-induced
amenorrhea and anorexia nervosa.  In addition,
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recent interventional studies in leptin deficient
children and observational studies in normal girls
and boys support a role for leptin as a permissive
factor for the initiation of puberty in children.
In this review we summarize leptin’s effects in
humans with particular emphasis for the roles of
leptin in childhood and adolescence.
The Physiology of Leptin
Leptin, from the Greek leptos meaning thin,
is the product of the Ob gene (1).  Leptin is
expressed primarily in white adipose tissue, but
also in the stomach, placenta, and the mammary
gland (4), and its tertiary structure suggests that
it belongs to the cytokine family.
Although fat mass is an important
determinant of leptin levels, other factors are
also of relevance, including acute changes in
caloric intake, gender, adipose tissue-specific
factors such as adipocyte size and visceral vs.
subcutaneous fat distribution, other hormonesKelesidis et al. 2 Vol.15 / No.1
(e.g. insulin, glucocorticoids) and cytokines (e.g.
TNF-α, IL-1) (5–8).
Leptin mediates its effect by binding to and
activating several specific leptin receptor isoforms
including the main signaling isoform i.e. the long
leptin receptor isoform (ObRb) (9, 10).  Leptin
receptor isoforms are found in many areas of the
brain (4) and in peripheral tissues, including the
lung, kidney, liver, pancreas, adrenals, ovaries,
haematopoietic stem cells, and skeletal muscle.
The soluble leptin receptor isoform functions as a
leptin-binding protein in the serum (11, 12–14).
The long leptin receptor isoform is a member
of the class I cytokine receptor family.  Leptin
binding to its long receptor isoform activates
several signal transduction pathways including
1) the JAK (Janus Kinase) signal transducer and
activator of transcription 3 (STAT3) pathway
(implicated in energy homeostasis) (15–17), 2)
the phosphatidylinositol-3-kinase (PI3K)
signaling pathway (important for food intake and
glucose homeostasis) (18), and 3) the mitogen-
activated-protein-kinase (MAPK) and the SHC/
Grb-2 –Ras pathways (implicated in cell
proliferation and/or differentiation) (19).  Leptin
signaling via the JAK-STAT signaling pathway is
inhibited by the induction of molecules such as
the suppressor of cytokine signaling protein-3
(SOCS-3) and protein tyrosine phosphatase-1B
(PTP-1B) which inhibit and/or decrease tyrosine
phosphorylation of JAK2, respectively (20, 21).
More studies are needed in order to fully
elucidate leptin’s signalling pathways.
Leptin has also an important role in the
regulation of hypothalamic neuropeptide
expression.  Leptin upregulates the expression
of anorexigenic neuropeptides such as
proopiomelanocortin (POMC) and cocaine- and
amphetamine-regulated transcript (CART) and
downregulates the expression of orexigenic
neuropeptides such as neuropeptide Y (NPY) and
agouti-related peptide (AgRP) (22).  Mutations
in almost every step in the pathway downstream
of leptin to melanocortin receptors (leptin,
leptin receptors, POMC, proconvertase-1,
melanocortin receptors 3 and 4) have been
described and are associated with obesity (23–
25).
Importantly, leptin alters the synaptic
plasticity of hypothalamic neurons in mice (26),
and acts as a neurotrophic factor during
hypothalamic development (27).  This is
consistent with its role in the development of
hypothalamic circuits regulating energy
homeostasis (28), but whether leptin has similar
effects in humans is an area of intensive research.
Regulation of Neuroendocrine Axes by Leptin
Leptin plays an important role in
reproduction (29).  Leptin receptors have been
identified at all levels of the hypothalamic-
pituitary-gonadal (HPG) axis, including anterior
pituitary (30), ovary (31), and endometrium (14).
In vitro, leptin stimulates gonadotropin-releasing
hormone (GnRH) pulsatility and release (32, 33).
Ob/ob mice, which are leptin-deficient, have
morbid obesity and sterility both of which are
corrected by leptin treatment (34–36).  Rare
cases of functional leptin deficiency in humans
due to mutations in the leptin or leptin receptor
gene, have also helped to clarify the role of leptin
in the regulation of the hypothalamic-gonadal axis
(37–44).  Specifically, leptin replacement therapy
results in significant loss of fat mass, development
of a pulsatile pattern of gonadotropin secretion
and reproductive maturity in leptin deficient
subjects (41, 42).  Administration of replacement-
dose r-metHuLeptin during fasting in healthy lean
men fully prevents the starvation-induced
decrease in LH pulsatility and testosterone levels
(45), indicating that leptin plays an important
role in the HPG axis of normal humans too (about
the role of leptin in puberty and in hypothalamic
amenorrhea see below).
In mice, acute starvation and stress increases
corticosterone and adrenocorticotropin (ACTH)
levels, whereas exogenous leptin administration3 Leptin in Children January 2006
reverses this activation of the hypothalamic-
pituitary-adrenal (HPA) axis by inhibiting
hypothalamic CRH (36, 43, 46).  Unlike mice,
the role of leptin in the regulation of the adrenal
axis in humans remains controversial (45).
Although observational studies have shown a
significant inverse relationship between
fluctuations in leptin, ACTH, and cortisol (7),
subjects with mutations in the leptin or leptin
receptor gene appear to have normal adrenal
function (40).  In addition, uncontrolled studies
have shown that leptin-deficient subjects may
have elevated basal cortisol and ACTH levels,
but normal urinary free cortisol and response to
dexamethasone suppression (39).  In placebo
controlled interventional studies in normal
humans leptin does not seem to have an effect
on adrenal steroids (45) but more studies are
needed to fully clarify this topic.
Leptin may have a role in the regulation of
hypothalamic-pituitary-GH-IGF-1 axis in rodents
and humans.  Leptin receptors are present in
normal pituitary tissue and pituitary adenomas
(47), and in vitro leptin increases GH secretion
from pituitary cells (48, 49).  Subjects with
functional leptin deficiency due to a leptin
receptor mutation had a mild but significant
growth delay during early childhood as well as
decreased GH secretion and low IGF-1 and
IGFBP-3 levels (40).  In healthy lean men, leptin
replacement during acute fasting partially
prevents the fall in IGF-1 but not free IGF-1 levels
during fasting, with no apparent effect of leptin
on IGFBP-1, 2, or 3 (45).  However, the effect of
leptin on IGF and IGF-BP during puberty and
later in life remains to be fully elucidated (39,
43, 45).
Recent evidence supports an interaction
between leptin and the hypothalamic-pituitary-
thyroid Axis (HPT) in both animals and humans
(36, 42, 50–53).  Subjects with mutations of the
leptin receptor have evidence of hypothalamic
hypothyroidism with low thyroxine, normal basal
TSH, and sustained TSH response to TRH (40).
In healthy men, leptin and TSH rhythms exhibit
a similar 24-h pattern of variability with
significant pattern synchrony of ultradian
fluctuations; this is impaired in leptin-deficient
subjects (54).  Additionally, in healthy lean men,
leptin administration in replacement doses
increased free T4 levels (within the normal
range) and significantly blunted the fasting-
induced decrease in TSH pulsatility.  This
indicates that the suppression of TSH associated
with fasting is mediated by leptin and that leptin
may have effects on free thyroxine levels (45).
Regulation of Bone Mineral Density by Leptin
Several studies have shown that leptin
directly stimulates bone growth in vitro and
increases bone density in leptin-deficient animals
(55–60), raising the possibility that low leptin
levels may contribute to bone loss in energy
deficient states such as hypothalamic amenorrhea
and anorexia nervosa.  It has also been reported
that leptin may cause bone loss in mice through
activation of the sympathetic nervous system
(SNS) (55–60), however.  In contrast, leptin does
not appear to influence the SNS in humans (61,
62) and observational studies (63–71) as well as
uncontrolled studies involving leptin treatment
of humans with congenital leptin deficiency (42)
and lipoatrophy (72) have failed to indicate a
role for leptin in regulating bone density.  Positive
(69, 73) negative (74, 75) or absent (68, 76)
associations between serum leptin levels and
bone mineral density have been reported in
observational studies in humans.  Thus, larger
placebo controlled clinical studies are therefore
necessary to determine the role of leptin in vivo
and to assess the contribution of the central and
peripheral role of leptin to the overall
maintenance of bone turnover in humans (77).Kelesidis et al. 4 Vol.15 / No.1
Regulation of Autonomic Function and
Blood Pressure by Leptin
Leptin may modulate blood pressure levels
in mice through either increasing norepinephrine
turnover and sympathetic nerve activity (78, 79)
or shifting the renal pressure-natriuresis curve,
leading to relative sodium retention (80), which,
in turn, result in increased blood pressure in
rodents (79, 81, 82).  A definite role of leptin in
the pathogenesis of hypertension in humans
remains to be demonstrated (83, 84) but our
own studies have failed to support a role for
leptin in regulating autonomic function or blood
pressure in humans (unpublished data).
Regulation of Immune Function by Leptin
It has been proposed that leptin plays an
important role in the interaction of metabolic
and immune systems (85).  Leptin deficient ob/
ob mice have several immune defects (86), and
leptin replacement protects the immune system
of leptin deficient ob/ob or starved mice from
lymphoid atrophy (87).  Deaths due to infections
during childhood have been reported to be more
frequent in humans with congenital leptin
deficiency but these studies remain anecdotal
(39).  Decreased serum leptin levels in infants
with malnutrition have been correlated with
reduced lymphoproliferative responses which are
reversed by weight gain (88).  Leptin ‘polarizes’
all levels of immune response towards a pro-
inflammatory (Th1) state (89, 90), and leptin
alone or in combination with other
immunostimulants induces proliferation and
activation of human peripheral blood monocytes/
macrophages and naïve lymphocytes
(CD4+CD45RA+) in vitro (91–93).  In humans,
recombinant human leptin (r-metHuLeptin),
administered in replacement doses, prevented
the starvation induced reduction of
CD4+CD45RA+  peripheral mononuclear blood
cells in normal subjects fasting for three days
(94).  In children with congenital absence of
leptin, leptin also reverses abnormal
immunophenotype, T cell hyporesponsiveness
and Th2 cytokine production (42).  Finally, in
women with hypothalamic amenorrhea and long
term leptin deficiency, leptin improved circulating
cytokine levels (94, 95).  In contrast, no change
in pro-inflammatory or other cytokine/chemokine
levels was observed in obese hyperleptinemic
diabetic subjects by further increasing the already
elevated serum leptin levels (irrespective of dose,
health status, or duration of treatment).  Thus,
leptin administration may have a role in immune
system modulation in leptin deficient subjects
(94), but does not appear to play an
etiopathogenic role in inflammation in leptin
replete states (95).
Regulation of Hematopoiesis
Expression of the leptin receptor OB-Rb has
been detected in yolk sac, fetal liver, bone
marrow and CD34+  cells as well as lympho-
hematopoietic fetal stromal and megakaryocytic
cell lines (96, 97).  Studies in vitro, as well as
observational studies in humans and animal
studies (97–99) suggest a role for leptin in the
induction of proliferation, differentiation and
functional activation of hematopoietic cells and
particularly the lymphocytic lineage (100), but
more studies are needed to fully clarify leptin’s
role in hematopoiesis.
Regulation of Energy Homeostasis by Leptin
a. Common obesity
Most obese humans have increased leptin
levels, indicating that human obesity is a leptin-
resistant state (2, 39).  Leptin resistance in obese
humans is attributed to defects in leptin transport
through the blood brain barrier to the
hypothalamus and/or to postreceptor defects
including induction of inhibitors of leptin
signaling in hypothalamic nuclei (101, 102).5 Leptin in Children January 2006
Further studies are warranted to clarify the
subset of obese individuals for whom r-
metHuLeptin treatment would have the greatest
effect in weight loss.  In this respect, it has been
proposed that heterozygotes for leptin gene
mutations are overweight or obese but relatively
hypoleptinemic and possibly more sensitive to
leptin treatment (103).
b. Obesity due to mutations of genes in the
leptin pathway
Mutations of the leptin gene or its receptor
in humans, although infrequent, underline the
importance of the leptin system in the control of
energy homeostasis, neuroendocrine and immune
function (103) (see above).  More than 15
subjects with congenital leptin deficiency have
been described to date.  These children are
normal at birth but develop morbid obesity in
early childhood which is responsive to leptin
treatment (38, 39, 41).  Additionally,
heterozygotes for leptin gene mutations have
relative hypoleptinemia which may predispose
these subjects to develop obesity (103).  Finally,
several mutations of molecules in the pathway
downstream of leptin have been identified as
causes of obesity in a significant percentage of
obese children (~ 6–8%).
c. Leptin in eating disorders
Leptin levels are low in the serum of patients
with anorexia nervosa who also have a relatively
higher transport of leptin to the cerebrospinal fluid
at lower serum leptin concentrations (104).  Levels
of the soluble leptin receptor, which represent
the main binding protein for leptin, are also higher
in patients with anorexia (105–108).  This results
in an even lower free leptin index and suggests a
role for leptin binding proteins in the regulation
of energy homeostasis.  In patients with anorexia
nervosa, who preferentially gain fat mass upon
refeeding, leptin levels increase in the
cerebrospinal fluid and seem to return to normal
before body mass index does (104).  Amenorrhea
and other neuroendocrine abnormalities, in
patients with anorexia nervosa and women
athletes who exercise strenuously, are closely
associated with low leptin levels reflecting low fat
content.  Thus, neuroendocrine function and
ovulation are inhibited when a certain amount of
nutritional reserves is absent.  We have recently
tested the hypothesis that low leptin levels in
women with hypothalamic amenorrhea (HA) may
be directly responsible for the reproductive and
hormonal abnormalities by administering
recombinant methionyl human leptin (r-
metHuLeptin) at replacement doses to women
with HA related to strenuous exercise or low
weight (109).  Thus, leptin is a necessary factor
for resumption of menses in patients with anorexia
nervosa (110), and increasing LH levels in
response to refeeding track increasing serum
leptin levels very closely (111).  Additional studies
are warranted to optimize the dose and duration
of r-metHuLeptin required to restore reproductive
and other neuroendocrine function without
inducing an undesirable degree of weight loss in
subjects who are already lean.
Leptin and Insulin Resistance
Administration of exogenous leptin to
genetically deficient ob/ob mice or mice with
congenital generalized lipodystrophy and severe
insulin resistance, improves insulin resistance and
hyperlipidemia (112, 113).  Subjects with
lipoatrophy (congenital or acquired) have lower
leptin levels.  Uncontrolled interventional studies
in more than 35 subjects to date demonstrate
that exogenous leptin administration to patients
with congenital lipodystrophy and insulin
resistance decreases insulin resistance,
suppresses hepatic gluconeogenesis, improves
hyperlipidemia (114–116) and reverses hepatic
steatosis (117).
Leptin has also a role in HIV infection and
the Highly Active Antiretroviral Therapy (HAART)
induced metabolic syndrome.  Importantly,Kelesidis et al. 6 Vol.15 / No.1
lipoatrophic HIV positive subjects on Highly Active
Antiretroviral Therapy (HAART) have low leptin
levels and leptin treatment in men with HIV
infection resulted in significant loss of central fat
mass, and improvement of insulin resistance and
hyperlipidemia (118), indicating that leptin may
have a role in regulating insulin sensitivity in
humans with relative leptin deficiency.  Large-
scale, placebo controlled interventional trials are
needed to fully elucidate the role of leptin in
insulin resistant states in humans.
Specific roles of Leptin in Childhood
and Adolescence
A significant role of leptin has been
established starting as early as neonatal life and
continues through adolescence (119).  Leptin
plays a role in major physiologic processes which
take place during these time periods including
growth, puberty and bone development and may
also underlie the development of diseases, which
manifest predominantly during adolescence and
early adulthood, such as hypothalamic
amenorrhea and eating disorders.
Leptin in the Neonate
The body weight and fat mass of the neonate
are positively associated with the level of leptin
in cord blood (120–123) derived from both the
placenta (124) and fetal tissues (122, 123).
Leptin decreases in response to maternal
smoking, is lower in preterm infants and those
who are small for gestational age, and is higher
in those who are large for gestational age (120).
Future studies are clearly required to determine
whether the intrauterine and early postnatal
nutrient environment programs the endocrine
feedback loop between adipose tissue and the
central and peripheral neuroendocrine systems
that regulate energy balance, resulting in an
enhanced risk of obesity in adult life (125).
It has been proposed that leptin may also
regulate growth (126) and promote
hematopoiesis and lymphopoiesis in newborn
infants (99).  Leptin is secreted in the breast
milk and can pass from the gastrointestinal tract
to the blood (127), suggesting that in addition to
neonatal leptin, maternal leptin in milk may, as
in rodents, play a role in regulating neonatal food
intake or growth (127).  In agreement with this
notion, it has recently been proposed that the
production of leptin in breast tissue by human
mammary epithelial cells might be regulated
physiologically according to necessity and state
of the infant (small, large, normal for gestational
age) (128).  In conclusion, there are many roles
of leptin in the neonatal period, which may have
importance for physiologic and pathophysiologic
processes later in life, but this area needs to be
studied further.
Leptin in Puberty
Inadequate nutrition delays or prevents the
onset of puberty (3), and leptin receptors have
been found in the ventromedial and arcuate
nuclei of the hypothalamus, regions anatomically
associated with both control of appetite and
reproductive endocrine function (129).  Leptin
may signal to the brain the existence of a critical
amount of fat stores necessary for initiation of
puberty and maintenance of menstrual cycles and
reproductive ability (130).  In normal children,
leptin levels increase before puberty as body fat
mass increases and reach their peak at the onset
of puberty, suggesting that leptin may trigger
puberty in humans (131, 132).  As stated above,
persons with leptin gene mutations or inactivating
mutations of the leptin receptor are morbidly
obese, remain prepubertal, and have
hypogonadotropic hypogonadism (40).  In a 9-
yr-old leptin-deficient child, leptin replacement
therapy for 12 mo resulted not only in marked
loss of fat mass, but also the development of a
pulsatile nocturnal pattern of gonadotropin
secretion consistent with early puberty (41).7 Leptin in Children January 2006
This progressed to normal LH and follicle-
stimulating hormone (FSH) pulsatility with
continued replacement therapy (42).  Our group
has shown that leptin levels increase prior to the
increase of circulating testosterone in
peripubertal boys (133) and that administration
of replacement-dose r-metHuLeptin during
fasting fully prevented the starvation-induced
decrease in LH pulsatility and testosterone levels
in healthy lean men (45).  These findings indicate
that falling leptin levels during short-term energy
deprivation in healthy men are responsible for
the food deprivation-induced decline in
reproductive hormones.  It may therefore be
concluded that leptin plays a role in the
regulation of reproduction and may be involved
in signaling the onset of puberty and the
maintenance of reproductive function thereafter.
Leptin and Hypothalamic Amenorrhea
Hypothalamic amenorrhea is defined by
cessation of menstruation secondary to
dysfunction of the hypothalamic pituitary gonadal
axis in the absence of organic disease or ovarian
failure.  Women with hypothalamic amenorrhea
secondary to intensive exercise or low weight
have serum leptin levels lower than those of BMI
adjusted controls, reflecting their relative energy
deficits.  To establish whether lower leptin levels
are etiologically linked with hypothalamic
amenorrhea, we have recently completed
interventional “proof-of-concept” studies
involving leptin administration to women with
hypothalamic amenorrhea.  We found that r-
metHuLeptin replacement improved LH
pulsatility, neuroendocrine and reproductive
function including ovulation, as well as ovarian
parameters measured by ultrasonography (109,
134).  A subsequent uncontrolled study in women
with generalized lipodystrophy and menstrual
irregularities or amenorrhea demonstrated that
chronic leptin replacement therapy restored
regular menses (135).  Further longer, placebo
controlled studies are needed to further clarify
the role of leptin in the pathogenesis and possibly
treatment of hypothalamic amenorrhea and
associated osteogenesis and/or infertility.
Other Roles of Leptin in Children and
Adolescents
According to recent studies leptin has also
been proposed to be involved in the pathogenesis
of other diseases such as asthma and cystic
fibrosis.  Leptin levels are elevated in children
with asthma (136), and children and adolescents
with cystic fibrosis had elevated leptin levels and
reduced gains in fat and fat-free mass (137).  It
remains unknown, whether the higher leptin
levels in those studies are causally related to
cystic fibrosis or asthma or whether they are
due to stimulatory effects of inflammatory
cytokines and whether they may contribute to
the anorexia, poor weight gain and growth of
those children.  Further basic and clinical
research is needed in this area.
Conclusions
 In conclusion, from the initial simplistic view
of leptin as an anti-obesity hormone we now have
a far greater understanding of the pleiotropic
nature of this hormone.  Leptin has an emerging
role in children and adolescents.  Leptin affects
important physiological processes such as
neuroendocrine, metabolic, immune, and
hematopoietic function, and has a central role in
disease states such as hypothalamic amenorrhea
and anorexia nervosa.  An enormous amount of
progress has been made in understanding leptin
physiology over the past 11 yr since this molecule
was first identified (from in vitro, animal, and
toxicology studies to human physiology and
proof-of-concept treatment studies), but more
studies are needed in order to fully elucidate the
role of leptin in human physiology and
pathophysiology.Kelesidis et al. 8 Vol.15 / No.1
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